drugset / Trial / NCT02091492
Teriparatide for Fracture Repair in Humans
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will test the hypothesis that daily subcuaneous administration of 20µg of teriparatide (TPTD) as compared to daily subcuaneous placebo for twelve weeks accelerates proximal 2-segment humerus fracture healing and improves the three dimensional structural properties of bone as measured via quantitative bone image analysis and finite element modeling assessed by quantitative computed tomography.
Timeline
- Start
- 2014-06
- Primary completion
- 2015-09
- Completion
- 2015-09
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Teriparatide | Protein / enzyme biologic | 20 ug | Subcutaneous |